知镜 Cognispect · 医学文献与研究工作台

Wangshi Baochi Pill for functional dyspepsia syndrome in infants and toddlers: a multicenter randomized placebo-controlled trial.

Ye L, Zhang L, Zhang B, Xie X, Xiong F, Ding Y, Li X, Huang T, Duan J, Li T, Wang Z, Zeng Y, Gao X, Feng D, Luo H, Chen P, Li K, Xie J, Zhao J, Xu W, Cheng Y, Chen H, Ding J, Zhen H, Sun Y, Geng L, Gong S.
Translational pediatrics · 2026-08-31 · PMID 42866128

文献摘要

Background Gastrointestinal discomfort in infants and toddlers is common, yet many cases may not meet the Rome IV diagnostic criteria, posing a challenge to clinical management. To address this gap, Chinese experts have proposed the novel diagnostic entity "functional dyspepsia syndrome in infants and toddlers" (FDSIT). Therapeutic options for functional gastrointestinal disorders in infants and toddlers remain considerably limited, particularly with regard to conventional Western pharmacotherapies. Wangshi Baochi Pill (WBP), a traditional Chinese medicine with a long history of pediatric use, has shown efficacy in older children (≥4 years) with functional dyspepsia. However, its efficacy and safety for FDSIT remain unclear. This study aimed to assess the efficacy and safety of WBP in infants and toddlers diagnosed with FDSIT according to the Chinese expert consensus. Methods This multicenter, randomized, double-blind, placebo-controlled trial was conducted across 15 hospitals in China. Eligible participants aged 1-36 months were randomly assigned (1:1, block size 4) to receive WBP (2 mg/kg twice daily) or a matching placebo for 7 days, with follow-up through day 14. The primary endpoint was the combined symptom effectiveness rate (CSER) at day 7, defined as the proportion of participants achieving a ≥50% reduction in total symptom score across five prespecified symptom domains, each graded on a 4‑point scale. Secondary endpoints included CSER at days 3 and 14, individual symptom remission rates, growth parameters, and adverse events (AEs), which were systematically monitored via diary cards and clinical assessments. Results There were 240 infants and toddlers randomized; 229 were included in the full analytical set (WBP, n=113; placebo, n=116). Baseline characteristics were well balanced. At day 7, CSER was significantly higher in the WBP group than in the placebo group [69.03% vs. 33.62%; absolute difference 35.41%, 95% confidence interval (CI): 23.30% to 47.51%; χ 2 =28.72, P vs. 43.97%; absolute difference 38.33%, 95% CI: 26.89% to 49.79%; χ 2 =36.04, P Conclusions In this trial, WBP demonstrated notable efficacy and a favorable short-term safety profile for the treatment of FDSIT. These findings suggest that WBP may represent a potential therapeutic option, although further confirmatory studies are warranted. Trial registration Chinese Clinical Trial Registry (ChiCTR), ChiCTR2300072543. Registered on 16 June 2023.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。